In July 2018, the European Medicines Agency (EMA) approved two CAR T products for the European market: tisagenlecleucel and axicabtagene ciloleucel. All other CAR T cells currently are investigational products. At the time of the meeting, more than 50 European centers were qualified to deliver CAR T cell therapy or in the process of becoming qualified within the next six months. The blocks below present an overview of CAR T cell activities in Europe.
Click on the blocks below to read more or to view webcasts.